Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

HPV Vaccination for Cervical Cancer Prevention is not Cost-Effective in Japan

  • Isshiki, Takahiro (Department of Hematology, Teikyo University Chiba Medical Center)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Our study objectives were to evaluate the medical economics of cervical cancer prevention and thereby contribute to cancer care policy decisions in Japan. Methods: Model creation: we created presence-absence models for prevention by designating human papillomavirus (HPV) vaccination for primary prevention of cervical cancer. Cost classification and cost estimates: we divided the costs of cancer care into seven categories (prevention, mass-screening, curative treatment, palliative care, indirect, non-medical, and psychosocial cost) and estimated costs for each model. Cost-benefit analyses: we performed cost-benefit analyses for Japan as a whole. Results: HPV vaccination was estimated to cost $291.5 million, cervical cancer screening $76.0 million and curative treatment $12.0 million. The loss due to death was $251.0 million and the net benefit was -$128.5 million (negative). Conclusion: Cervical cancer prevention was not found to be cost-effective in Japan. While few cost-benefit analyses have been reported in the field of cancer care, these would be essential for Japanese policy determination.

Keywords

References

  1. Boardman AE, Greenberg DH, Vining AR, et al (2011). Cost-Benefit Analysis: Concepts and Practice, 4th edition. Pearson, Upper Saddle River, NJ, 408-13.
  2. Bosch FX, Manos MM, Munoz N, et al (1995). Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst, 87, 796-802. https://doi.org/10.1093/jnci/87.11.796
  3. Choi JW, Cho KH, Choi Y, et al (2014). Changes in economic status of households associated with catastrophic health expenditures for cancer in South Korea. Asian Pac J Cancer Prev, 15, 2713-7. https://doi.org/10.7314/APJCP.2014.15.6.2713
  4. Ghotbi N, Anai A (2012). Assessment of the knowledge and attitude of female students towards cervical cancer prevention at an international university in Japan. Asian Pac J Cancer Prev, 13, 897-900. https://doi.org/10.7314/APJCP.2012.13.3.897
  5. Hanley S, Konno R (2010). HPV vaccine: Catch-up vaccination including women in 40s. Sanka to Fujinka, 9, 1016-22.
  6. Harper DM, Franco EL, Wheeler C, et al (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet, 364, 1757-65. https://doi.org/10.1016/S0140-6736(04)17398-4
  7. Igakutushinsya (2014). Diagnosis Procedure Combination Score Chart. Igakutushinsya, Tokyo, 242-4.
  8. Isshiki T, Kimura Y, Takei N, et al (2013). Estimation of travel time and costs required for patients with cancer to receive outpatient treatment using electronic medical record data. American Society of Clinical Oncology's Quality Care Symposium. http://meetinglibrary.asco.org/content/120043-140 (accessed July 3, 2014).
  9. Iyaku-Joho-Kenkyujo (2012). Drugs in Japan. Ed Iyaku-Joho-Kenkyujo, JIHO, Tokyo, 1182-6.
  10. Japan Association of Obstetricians and Gynecologists (2014). Reporter conference. http://www.jaog.or.jp/all/conference/post_293.php (accessed July 3, 2014).
  11. Japan Society of Gynecologic Oncology (2011). Cervical cancer treatment guideline, Ed Japan Society of Gynecologic Oncology. Kaneharashuppan, Tokyo, 110-21.
  12. Kurata T, Miyahara M. (2014). Koutujiko-Songaibaisho-Hikkei. Eds Kurata T and Miyahara M. SHINNIPPON-HOKI PUBLISHING, Tokyo. ???
  13. Ministry of Health, Labor and Welfare (2014). Basic survey on wage structure. http://www.e-stat.go.jp/SG1/estat/List.do?bid=000001044250&cycode=0 (accessed July 3, 2014).
  14. Ministry of Health, Labor and Welfare (2014). Cervical cancer prevention vaccine FAQ. www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou28/qa_shikyukeigan_vaccine.html (accessed July 3, 2014)
  15. Ministry of Internal Affairs and Communications, Statistics Bureau (2014). Population estimates. www.stat.go.jp/data/jinsui/ (accessed July 3, 2014).
  16. National Cancer Center (2013). Monitoring of cancer incidence in Japan - survival 2003-2005 report. Center for Cancer Control and Information Services, National Cancer Center.
  17. NICHIBENREN (2013). Civil traffic accidents litigation Computation standards for damage payments. Ed NICHIBENREN Traffic Accident Consultation Center, Tokyo.
  18. Organization for Economic Co-operation and Development (OECD) Health Working Papers (2006). Health care quality indicators projects 2006 data collections update report. http://www.oecd.org/health/health-systems/39447928.pdf (accessed July 3, 2014).
  19. Prasad SR, Hill R (2008). Cost-benefit analysis on the HPV vaccine in Medicaid-enrolled females of the Appalachian region of Kentucky. J Ky Med Assoc, 106, 271-6.
  20. Rodriquez AC, Solomon D, Herrero R, et al (2013). Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy and treatment. Am J Epidemiol, 178, 752-60. https://doi.org/10.1093/aje/kwt047
  21. Uchida A, Tango M, Hosokawa K, et al (2010). Cost-benefit analysis: cervical cancer vaccination. http://www.pp.u-tokyo.ac.jp/courses/2010/documents/graspp2010-5113090-3.pdf (accessed July 3, 2014).

Cited by

  1. Regarding 'HPV Vaccination for Cervical Cancer Prevention is not Cost-effective in Japan' vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2583